Page 3 - கழுத்து மருத்துவ புற்றுநோயியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Date Time Neoadjuvant combination immunotherapy improves outcomes for early stage non-small cell lung cancer The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory. Researchers from The University of Texas MD Anderson Cancer Center published the study results today in Nature Medicine. The NEOSTAR trial tested combined neoadjuvant therapy of nivolumab plus ipilimumab, as well as neoadjuvant nivolumab monotherapy in patients with operable NSCLC. The trial met its prespecified primary endpoint efficacy threshold in the combination arm, with eight of 21 treated patients (38%) achieving major pathological response, defined as ≤10% viable tumor at surgery. MPR has been show

United statesBoris sepesiTina casconeBob mayberry foundationUniversity of texas md anderson cancer centerNational institutes of health cancer instituteConnie rasor endowment for cancer researchMd anderson moon shots programMd anderson physician scientist programRexanna foundation for fighting lung cancerBristol myers squibbTranslation molecular profiling laboratoryKhalifa bin zayed al nahyan foundationCancer centerNeck medical oncologyLung cancer moon